
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3395099/publications.pdf Version: 2024-02-01



NEIL VASDEV

#	Article	IF	CITATIONS
1	Imaging of astrocytes in posttraumatic stress disorder: A PET study with the monoamine oxidase B radioligand [11C]SL25.1188. European Neuropsychopharmacology, 2022, 54, 54-61.	0.7	16
2	Cognitive impairment and World Trade Centre-related exposures. Nature Reviews Neurology, 2022, 18, 103-116.	10.1	18
3	Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy. Brain Communications, 2022, 4, fcac019.	3.3	3
4	PET imaging of glycogen synthase kinase-3 in pancreatic cancer xenograft mouse models American Journal of Nuclear Medicine and Molecular Imaging, 2022, 12, 1-14.	1.0	0
5	Editorial: Positron Emission Tomography (PET) Imaging of Brain Biochemistry: Beyond High-Affinity Radioligands. Frontiers in Neuroscience, 2022, 16, 907460.	2.8	1
6	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nature Communications, 2022, 13, 2810.	12.8	10
7	Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharmaceutica Sinica B, 2021, 11, 373-393.	12.0	82
8	Repurposing ¹¹ C-PS13 for PET Imaging of Cyclooxygenase-1 in Ovarian Cancer Xenograft Mouse Models. Journal of Nuclear Medicine, 2021, 62, 665-668.	5.0	6
9	On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.6	43
10	Radiosynthesis, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [¹⁸ F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. ACS Chemical Neuroscience, 2021, 12, 596-602.	3.5	29
11	Fluorine-18 labelled Ruppert–Prakash reagent ([¹⁸ F]Me ₃ SiCF ₃) for the synthesis of ¹⁸ F-trifluoromethylated compounds. Chemical Communications, 2021, 57, 5286-5289.	4.1	8
12	<i>In Vitro</i> Evaluation of [³ H]CPPC as a Tool Radioligand for CSF-1R. ACS Chemical Neuroscience, 2021, 12, 998-1006.	3.5	19
13	Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of ¹¹ C-Labeled ALK2 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 846-850.	2.8	5
14	Preclinical Evaluation of TSPO and MAO-B PET Radiotracers in an LPS Model of Neuroinflammation. PET Clinics, 2021, 16, 233-247.	3.0	15
15	Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of CSK-3. Journal of Fluorine Chemistry, 2021, 245, 109760.	1.7	8
16	Artificial intelligence for molecular neuroimaging. Annals of Translational Medicine, 2021, 9, 822-822.	1.7	6
17	In Vitro and In Vivo Evaluation of GSK-3 Radioligands in Alzheimer's Disease: Preliminary Evidence of Sex Differences. ACS Pharmacology and Translational Science, 2021, 4, 1287-1294.	4.9	7
18	A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population. International Journal of Environmental Research and Public Health, 2021, 18, 681.	2.6	10

#	Article	IF	CITATIONS
19	Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. Journal of Medicinal Chemistry, 2021, 64, 123-149.	6.4	33
20	Cardiac Sympathetic Positron Emission Tomography Imaging with Meta-[18F]Fluorobenzylguanidine is Sensitive to Uptake-1 in Rats. ACS Chemical Neuroscience, 2021, 12, 4350-4360.	3.5	3
21	Repurposing [11C]MC1 for PET Imaging of Cyclooxygenase-2 in Colorectal Cancer Xenograft Mouse Models. Molecular Imaging and Biology, 2021, , 1.	2.6	0
22	Radiosynthesis of [11C]Ibrutinib via Pd-Mediated [11C]CO Carbonylation: Preliminary PET Imaging in Experimental Autoimmune Encephalomyelitis Mice. Frontiers in Nuclear Medicine, 2021, 1, .	1.2	8
23	Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions. Molecular Imaging, 2020, 19, 153601212093639.	1.4	3
24	Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [¹¹ C]Tolebrutinib, via palladiumâ€NiXantphosâ€mediated carbonylation. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 482-487.	1.0	15
25	Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. Biological Psychiatry, 2020, 88, 649-656.	1.3	32
26	Training the next generation of radiopharmaceutical scientists. Nuclear Medicine and Biology, 2020, 88-89, 10-13.	0.6	7
27	Classics in Neuroimaging: Imaging the Endocannabinoid Pathway with PET. ACS Chemical Neuroscience, 2020, 11, 1855-1862.	3.5	13
28	Classics in Neuroimaging: Development of Positron Emission Tomography Tracers for Imaging the GABAergic Pathway. ACS Chemical Neuroscience, 2020, 11, 2039-2044.	3.5	9
29	Revisiting the Radiosynthesis of [18F]FPEB and Preliminary PET Imaging in a Mouse Model of Alzheimer's Disease. Molecules, 2020, 25, 982.	3.8	11
30	Copper(I)-Mediated 11C-Carboxylation of (Hetero)arylstannanes. ACS Omega, 2020, 5, 8242-8250.	3.5	14
31	Synthesis, in vitro and in vivo evaluation of 11C-O-methylated arylpiperazines as potential serotonin 1A (5-HT1A) receptor antagonist radiotracers. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 13.	3.9	5
32	Aryl- ¹⁸ F Bond Formation from Nucleophilic [¹⁸ F]fluoride. , 2020, , 617-648.		2
33	Chemistry for Positron Emission Tomography: Recent Advances in ¹¹ Câ€; ¹⁸ Fâ€; ¹³ Nâ€; and ¹⁵ O‣abeling Reactions. Angewandte Chemie - International Edition, 2019, 58, 2580-2605.	13.8	216
34	Improving PET Imaging Acquisition and Analysis With Machine Learning: A Narrative Review With Focus on Alzheimer's Disease and Oncology. Molecular Imaging, 2019, 18, 153601211986907.	1.4	27
35	Structural Basis for Achieving GSK-3Î ² Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. Journal of Medicinal Chemistry, 2019, 62, 9600-9617.	6.4	31
36	"Inâ€loop― ¹⁸ Fâ€fluorination: A proofâ€ofâ€concept study. Journal of Labelled Compounds a Radiopharmaceuticals, 2019, 62, 292-297.	nd _{1.0}	7

#	Article	IF	CITATIONS
37	Synthesis and preclinical evaluation of [18F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1624-1627.	2.2	15
38	Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "Tail Switching―Strategy on a Piperazinyl Azetidine Skeleton. Journal of Medicinal Chemistry, 2019, 62, 3336-3353.	6.4	28
39	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. JAMA Psychiatry, 2019, 76, 634.	11.0	74
40	Facile 18F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR5 PET radiopharmaceutical [18F]FPEB. Nature Protocols, 2019, 14, 1530-1545.	12.0	27
41	Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. ACS Chemical Neuroscience, 2019, 10, 1867-1871.	3.5	42
42	Chemie der Positronenemissionstomographie: Aktuelle Fortschritte bei ¹¹ Câ€, ¹⁸ Fâ€, ¹³ N―und ¹⁵ Oâ€Markierungsreaktionen. Angewandte Chemie, 2 131, 2604-2631.	029)	31
43	EXTH-49. THERAPEUTIC EFFICACY OF ENGINEERED, HYDROGEL ENCAPSULATED BIMODAL MSC IN GLIOBLASTOMA STRATIFIED ON CELL SURFACE RECEPTOR EXPRESSION. Neuro-Oncology, 2019, 21, vi93-vi93.	1.2	0
44	In Vitro and in Vivo Evaluation of ¹¹ C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies. Journal of Medicinal Chemistry, 2018, 61, 2278-2291.	6.4	41
45	Recent applications of a single quadrupole mass spectrometer in 11C, 18F and radiometal chemistry. Journal of Fluorine Chemistry, 2018, 210, 46-55.	1.7	6
46	Recent Advances in ¹⁸ F Radiochemistry: A Focus on B- ¹⁸ F, Si- ¹⁸ F, Al- ¹⁸ F, and C- ¹⁸ F Radiofluorination via Spirocyclic Iodonium Ylides. Journal of Nuclear Medicine, 2018, 59, 568-572.	5.0	50
47	Sifting through the surfeit of neuroinflammation tracers. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 204-224.	4.3	92
48	Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [¹¹ C]PBT2. Molecular Pharmaceutics, 2018, 15, 695-702.	4.6	11
49	"Inâ€loop―[¹¹ C]CO ₂ fixation: Prototype and proof of concept. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 252-262.	1.0	23
50	Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. Molecular Imaging, 2018, 17, 153601211879231.	1.4	158
51	Fluorine-18: an untapped resource in inorganic chemistry. Chemical Communications, 2018, 54, 11835-11842.	4.1	6
52	Development of [¹⁸ F]Maleimide-Based Glycogen Synthase Kinase-3β Ligands for Positron Emission Tomography Imaging. ACS Medicinal Chemistry Letters, 2017, 8, 287-292.	2.8	22
53	Synthesis and Reactivity of ¹⁸ F-Labeled α,α-Difluoro-α-(aryloxy)acetic Acids. Organic Letters, 2017, 19, 568-571.	4.6	13
54	cGMP production of the radiopharmaceutical [¹⁸ F]MK-6240 for PET imaging of human neurofibrillary tangles. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 263-269.	1.0	27

#	Article	IF	CITATIONS
55	Metal-free ¹⁸ F-labeling of aryl-CF ₂ H via nucleophilic radiofluorination and oxidative C–H activation. Chemical Communications, 2017, 53, 126-129.	4.1	24
56	[¹¹ C]Cyanation of arylboronic acids in aqueous solutions. Chemical Communications, 2017, 53, 6597-6600.	4.1	41
57	A Facile Radiolabeling of [¹⁸ F]FDPA via Spirocyclic Iodonium Ylides: Preliminary PET Imaging Studies in Preclinical Models of Neuroinflammation. Journal of Medicinal Chemistry, 2017, 60, 5222-5227.	6.4	43
58	Novel PET Radiotracers with Potential Clinical Applications. PET Clinics, 2017, 12, xi-xii.	3.0	4
59	Stereoselective ¹¹ C Labeling of a "Native―Tetrapeptide by Using Asymmetric Phaseâ€Transfer Catalyzed Alkylation Reactions. European Journal of Organic Chemistry, 2017, 2017, 1019-1024.	2.4	11
60	Discovery of PET radiopharmaceuticals at the academia-industry interface. Drug Discovery Today: Technologies, 2017, 25, 19-26.	4.0	14
61	Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET. Molecular Imaging, 2017, 16, 153601211773666.	1.4	21
62	The Search for a Subtype-Selective PET Imaging Agent for the GABA _A Receptor Complex: Evaluation of the Radiotracer [¹¹ C]ADO in Nonhuman Primates. Molecular Imaging, 2017, 16, 153601211773125.	1.4	8
63	Classics in Neuroimaging: Imaging the Dopaminergic Pathway with PET. ACS Chemical Neuroscience, 2017, 8, 1817-1819.	3.5	15
64	¹⁸ Fâ€Labeling of Sensitive Biomolecules for Positron Emission Tomography. Chemistry - A European Journal, 2017, 23, 15553-15577.	3.3	75
65	Frontispiece: ¹⁸ Fâ€Labeling of Sensitive Biomolecules for Positron Emission Tomography. Chemistry - A European Journal, 2017, 23, .	3.3	0
66	Pharmacokinetic Evaluation of the Tau PET Radiotracer ¹⁸ F-T807 (¹⁸ F-AV-1451) in Human Subjects. Journal of Nuclear Medicine, 2017, 58, 484-491.	5.0	73
67	Microfluidic radiosynthesis of [¹⁸ F]FEMPT, a high affinity PET radiotracer for imaging serotonin receptors. Beilstein Journal of Organic Chemistry, 2017, 13, 2922-2927.	2.2	8
68	Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics. International Journal of Medicinal Chemistry, 2017, 2017, 1-8.	2.2	5
69	Synthesis and Preclinical Evaluation of Sulfonamido-based [¹¹ C- <i>Carbonyl</i>]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase. Theranostics, 2016, 6, 1145-1159.	10.0	50
70	Design and Prototype of an Automated Column-Switching HPLC System for Radiometabolite Analysis. Pharmaceuticals, 2016, 9, 51.	3.8	4
71	Enzymeâ€Mediated Modification of Singleâ€Domain Antibodies for Imaging Modalities with Different Characteristics. Angewandte Chemie - International Edition, 2016, 55, 528-533.	13.8	42
72	Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(<scp>iii</scp>) ylides. Chemical Science, 2016, 7, 4407-4417.	7.4	104

#	Article	IF	CITATIONS
73	Preclinical PET Neuroimaging of [¹¹ C]Bexarotene. Molecular Imaging, 2016, 15, 153601211666305.	1.4	8
74	Radiosynthesis and preliminary PET evaluation of 18 F-labeled 2-(1-(3-fluorophenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl)benzonitrile for imaging AMPA receptors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4857-4860.	2.2	16
75	Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells. Journal of Hematology and Oncology, 2016, 9, 93.	17.0	30
76	Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurology, 2016, 73, 1334.	9.0	182
77	Synthesis of ¹⁸ Fâ€Difluoromethylarenes from Aryl (Pseudo) Halides. Angewandte Chemie - International Edition, 2016, 55, 10786-10790.	13.8	38
78	Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease. Annals of Neurology, 2016, 79, 110-119.	5.3	778
79	Discovery of a Highly Selective Glycogen Synthase Kinaseâ€3 Inhibitor (PFâ€04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging. Angewandte Chemie - International Edition, 2016, 55, 9601-9605.	13.8	68
80	¹¹ Cî€O bonds made easily for positron emission tomography radiopharmaceuticals. Chemical Society Reviews, 2016, 45, 4708-4726.	38.1	98
81	Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([¹¹ C]MPPO) Based on α-Ketoheterocyclic Scaffold. ACS Chemical Neuroscience, 2016, 7, 109-118.	3.5	17
82	Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors. Current Topics in Medicinal Chemistry, 2016, 16, 1830-1842.	2.1	22
83	<i>Ortho</i> â€Stabilized ¹⁸ Fâ€Azido Click Agents and their Application in PET Imaging with Singleâ€Stranded DNA Aptamers. Angewandte Chemie - International Edition, 2015, 54, 12777-12781.	13.8	62
84	Validating novel tau positron emission tomography tracer <scp>[Fâ€18]â€AVâ€1451 (T807)</scp> on postmortem brain tissue. Annals of Neurology, 2015, 78, 787-800.	5.3	535
85	Practical Radiosynthesis and Preclinical Neuroimaging of [11C]isradipine, a Calcium Channel Antagonist. Molecules, 2015, 20, 9550-9559.	3.8	2
86	Total Radiosynthesis: Thinking Outside â€~the Box'. Australian Journal of Chemistry, 2015, 68, 1319.	0.9	25
87	P2-151: Imaging tau pathology in vivo in ftld with [18F] T807 PET. , 2015, 11, P545-P545.		0
88	Iodonium Ylide–Mediated Radiofluorination of ¹⁸ F-FPEB and Validation for Human Use. Journal of Nuclear Medicine, 2015, 56, 489-492.	5.0	65
89	Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader. Clinical Cancer Research, 2015, 21, 1340-1347.	7.0	32
90	Synthesis and Preclinical Evaluation of [18F]FCHC for Neuroimaging of Fatty Acid Amide Hydrolase. Molecular Imaging and Biology, 2015, 17, 257-263.	2.6	10

#	Article	IF	CITATIONS
91	PET Neuroimaging Studies of [¹⁸ F]CABS13 in a Double Transgenic Mouse Model of Alzheimer's Disease and Nonhuman Primates. ACS Chemical Neuroscience, 2015, 6, 535-541.	3.5	23
92	Synthesis of 18F-arenes from spirocyclic iodonium(III) ylides via continuous-flow microfluidics. Journal of Fluorine Chemistry, 2015, 178, 249-253.	1.7	20
93	¹⁸ F-Labeled Single-Stranded DNA Aptamer for PET Imaging of Protein Tyrosine Kinase-7 Expression. Journal of Nuclear Medicine, 2015, 56, 1780-1785.	5.0	59
94	Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2015, 6, 1025-1029.	2.8	41
95	Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles. Chemical Science, 2015, 6, 225-236.	7.4	107
96	Radiosynthesis and ex vivo evaluation of [18F]-(S)-3-(6-(3-fluoropropoxy)benzo[d]isoxazol-3-yl)-5-(methoxymethyl)oxazolidin-2-one for imaging MAO-B with PET. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 288-291.	2.2	15
97	Evaluating the accuracy of density functional theory for calculating 1H and 13C NMR chemical shifts in drug molecules. Computational and Theoretical Chemistry, 2015, 1051, 161-172.	2.5	18
98	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 883-889.	4.3	83
99	Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 323-331.	1.0	39
100	Microfluidic continuous-flow radiosynthesis of [¹⁸ F]FPEB suitable for human PET imaging. MedChemComm, 2014, 5, 432-435.	3.4	37
101	Synthesis of [¹¹ C]Bexarotene by Cu-Mediated [¹¹ C]Carbon Dioxide Fixation and Preliminary PET Imaging. ACS Medicinal Chemistry Letters, 2014, 5, 668-672.	2.8	39
102	Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics. Nature Communications, 2014, 5, 4365.	12.8	207
103	PET Imaging of Fatty Acid Amide Hydrolase with [¹⁸ F]DOPP in Nonhuman Primates. Molecular Pharmaceutics, 2014, 11, 3832-3838.	4.6	18
104	Radiosynthesis and ex vivo evaluation of [11C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors. Nuclear Medicine and Biology, 2014, 41, 688-694.	0.6	34
105	First Human Use of a Radiopharmaceutical Prepared by Continuous-Flow Microfluidic Radiofluorination: Proof of Concept with the Tau Imaging Agent [¹⁸ F]T807. Molecular Imaging, 2014, 13, 7290.2014.00025.	1.4	32
106	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
107	F4-01-04: TAU PET USING F18-T807: INITIAL EXPERIENCE IN NORMAL ELDERLY AND AD DEMENTIA. , 2014, 10, P242-P242.		1
108	11CO2 fixation: a renaissance in PET radiochemistry. Chemical Communications, 2013, 49, 5621.	4.1	92

#	Article	IF	CITATIONS
109	Rapid microfluidic flow hydrogenation for reduction or deprotection of 18F-labeled compounds. Chemical Communications, 2013, 49, 8755.	4.1	30
110	Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase. Nuclear Medicine and Biology, 2013, 40, 740-746.	0.6	28
111	Radiosynthesis and Evaluation of [¹¹ C- <i>Carbonyl</i>]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography. Journal of Medicinal Chemistry, 2013, 56, 201-209.	6.4	42
112	Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorganic and Medicinal Chemistry, 2013, 21, 4351-4357.	3.0	29
113	A concise radiosynthesis of the tau radiopharmaceutical, [¹⁸ F]T807. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 736-740.	1.0	70
114	PET radiopharmaceuticals for probing enzymes in the brain. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 194-216.	1.0	19
115	Synthesis and PET imaging studies of [18F]2-fluoroquinolin-8-ol ([18F]CABS13) in transgenic mouse models of Alzheimer's disease. MedChemComm, 2012, 3, 1228.	3.4	29
116	Development of new carbon-11 labelled radiotracers for imaging GABAA- and GABAB-benzodiazepine receptors. Bioorganic and Medicinal Chemistry, 2012, 20, 4482-4488.	3.0	25
117	The Assay of Enzyme Activity by Positron Emission Tomography. Neuromethods, 2012, , 111-135.	0.3	7
118	Radiosynthesis and in vivo tumor uptake of 2-deoxy-2-[18F]fluoro-myo-inositol. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6148-6150.	2.2	6
119	Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [11C-carbonyl] AR-A014418 by [11C]CO2 fixation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2099-2101.	2.2	33
120	[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nuclear Medicine and Biology, 2011, 38, 247-253.	0.6	76
121	Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nuclear Medicine and Biology, 2011, 38, 953-959.	0.6	15
122	Development of new radiopharmaceuticals for imaging monoamine oxidase B. Nuclear Medicine and Biology, 2011, 38, 933-943.	0.6	40
123	Synthesis and in vitro evaluation of derivatives of the β1-adrenergic receptor antagonist HX-CH 44. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5506-5509.	2.2	6
124	A rapid oneâ€step radiosynthesis of [¹¹ C]â€ <i>d</i> â€ <i>threo</i> â€methylphenidate. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 168-170.	1.0	3
125	Radiosynthesis of [¹¹ C]SL25.1188 via [¹¹ C]CO ₂ fixation for imaging monoamine oxidase B. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 678-680.	1.0	67
126	Synthesis and Application of Isocyanates Radiolabeled with Carbonâ€11. Chemistry - A European Journal, 2011, 17, 259-264.	3.3	73

#	Article	IF	CITATIONS
127	Regioselective ring opening of 2-methylaziridine derivatives with 18F- and 19F-fluoride. Tetrahedron Letters, 2011, 52, 4114-4116.	1.4	16
128	A New F-18 Labeled PET Agent For Imaging Alzheimer's Plaques. , 2011, , .		1
129	(E)-2-(2-Methylcyclohexylidene)hydrazinecarbothioamide. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o3005-o3005.	0.2	0
130	Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT. Molecules, 2010, 15, 8260-8278.	3.8	53
131	[11C]-URB694 for FAAH PET imaging: A novel radiotracer for a new target. NeuroImage, 2010, 52, S24.	4.2	2
132	Direct fixation of [¹¹ C]-CO ₂ by amines: formation of [¹¹ C-carbonyl]-methylcarbamates. Organic and Biomolecular Chemistry, 2010, 8, 428-432.	2.8	64
133	NMR Spectroscopic Evidence for the Intermediacy of XeF ₃ ^{â⁻'} in XeF ₂ /F ^{â⁻'} Exchange, Attempted Syntheses and Thermochemistry of XeF ₃ ^{â⁻'} Salts, and Theoretical Studies of the XeF ₃ ^{â⁻'} Anion. Inorganic Chemistry, 2010, 49, 8997-9004.	4.0	17
134	Utility of commercial radiosynthetic modules in captive solvent [¹¹ C]â€methylation reactions. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 490-492.	1.0	31
135	[18F]Fluoroamines via ring-opening of N-Cbz-2-methylaziridine with [18F]-fluoride. Tetrahedron Letters, 2009, 50, 544-547.	1.4	21
136	An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP. Applied Radiation and Isotopes, 2009, 67, 611-616.	1.5	20
137	Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chemical Communications, 2009, , 5527.	4.1	17
138	Synthesis and preliminary evaluation of [18F]-fluoro-(2S)-Exaprolol for imaging cerebral β-adrenergic receptors with PET. Neurochemistry International, 2008, 53, 173-179.	3.8	10
139	Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nuclear Medicine and Biology, 2008, 35, 305-314.	0.6	181
140	Facile Radiosynthesis of Fluorine-18 Labeled Î ² -Blockers. Synthesis, Radiolabeling, and ex Vivo Biodistribution of [¹⁸ F]-(2 <i>S</i> and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td (2 <i>R</i>)-1- Chemistry, 2008, 51, 5093-5100.	(1-Fluorop 6.4	oropan-2-ylan
141	N-Isopropylbenzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1005-o1005.	0.2	3
142	Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [18F]F-PHNO. Nuclear Medicine and Biology, 2007, 34, 195-203.	0.6	24
143	Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography. Synapse, 2006, 60, 314-318.	1.2	11
144	Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): A radiolabelled glycogen synthase kinase-3β specific inhibitor for PET studies. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5270-5273.	2.2	57

#	Article	IF	CITATIONS
145	On The Preparation of Fluorine-18 Labelled XeF2and Chemical Exchange between Fluoride Ion and XeF2. Journal of the American Chemical Society, 2002, 124, 12863-12868.	13.7	28
146	The effect of aromatic fluorine substitution in l-DOPA on the in vivo behaviour of []2-, []5- and []6-fluoro-l-DOPA in the human brain. Journal of Fluorine Chemistry, 2002, 115, 33-39.	1.7	12